Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00381472|
Recruitment Status : Completed
First Posted : September 27, 2006
Last Update Posted : March 23, 2017
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Drug: Ropinirole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||393 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa|
|Study Start Date :||June 2003|
|Actual Study Completion Date :||December 2004|
- Mean change from baseline in awake time "off" at Week 24 LOCF (last observation carried forward).
- Mean change from baseline in:
- amount and percent of awake time spent "on"
- percent awake time spent "off"
- Unified Parkinson's Disease Rating Scale (UPDRS) total motor score
- UPDRS Activities of Daily Living score
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00381472
Show 76 Study Locations
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|